Screener
Eton Pharmaceuticals, Inc. ETON License — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | For the three months ended / March 31, 2026 | For the three months ended / March 31, 2025 |
|---|---|---|
| Revenues: | ||
| Licensing revenue | — | $3,286 |
| Product sales and royalties, net | 24,266 | 13,996 |
| Total net revenues | 24,266 | 17,282 |
| Cost of sales: | ||
| Licensing revenue | — | 825 |
| Product sales and royalties | 9,531 | 6,596 |
| Total cost of sales | 9,531 | 7,421 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s license — revenue?
- Eton Pharmaceuticals, Inc. (ETON) reported license — revenue of $0 in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s license — revenue changed year-over-year?
- Eton Pharmaceuticals, Inc.'s license — revenue decreased by 100.0% year-over-year, from $3.29M to $0.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s license — revenue?
- Over 4 years (2021 to 2025), Eton Pharmaceuticals, Inc.'s license — revenue has grown at a -35.5% compound annual growth rate (CAGR), from $19M to $3.29M.
- What does license — revenue mean?
- Represents the total gross revenue recognized from licensing agreements, excluding any collected sales taxes. This metric captures the core income generated from granting third parties the rights to utilize the company's intellectual property or pharmaceutical assets. It serves as a primary indicator of the commercial success and market demand for the company's licensed portfolio.
Ask your AI about Eton Pharmaceuticals, Inc.'s license — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude